Pfizer Clinical Research Unit

The site is advancing research in heart failure with preserved ejection fraction, aiming to evaluate innovative therapies that could improve cardiac function and patient quality of life.

• Cardiac hemodynamics and biomarkers
• Patient‑reported outcome measures
• Novel drug delivery strategies
• Safety profiling in diverse populations

Pfizer Clinical Research Unit in Brussels supports these studies with state‑of‑the‑art facilities and expert investigators.

Investigators focus on ulcerative colitis and related inflammatory bowel conditions, seeking to test new oral agents that promote mucosal healing and reduce disease activity.

• Endoscopic assessment of inflammation
• Biomarkers of intestinal permeability
• Quality‑of‑life questionnaires
• Comparative efficacy of emerging therapies

The research team leverages a hybrid decentralized trial model to enhance patient participation.

Studies address immune‑mediated inflammatory disorders such as rheumatoid arthritis and alopecia areata, aiming to expand treatment options that modulate immune pathways.

• Cytokine signaling inhibition
• Joint imaging and structural outcomes
• Skin autoimmunity assessments
• Long‑term safety monitoring

Pfizer’s Brussels unit collaborates with leading rheumatology and dermatology centers to accelerate these efforts.

The program explores therapies for atopic dermatitis, vitiligo, and related skin disorders, with the goal of restoring barrier function and pigmentation.

• Dermatologic scoring systems
• Pigment restoration metrics
• Immune cell profiling in skin tissue
• Patient‑centered outcome measures

Research at the Pfizer Clinical Research Unit combines clinical expertise with innovative trial designs to improve patient outcomes.